Retrotrope is changing aging as we know it, so that people do not have to suffer the
ravages of many degenerative diseases. Retrotope is a pharmaceutical company
startup that is leading the advance of a revolutionary new unified theory of cellular
degeneration that can result in dramatically new approaches to therapy. This theory is
based on three groundbreaking discoveries:
- Many disparate degenerative diseases share a common weakness.
- That weakness is one type of chemical bond that makes membrane fats susceptible to oxidation damage and loss of function.
- By strengthening that bond, we are able to prevent and even reverse disease damage.
Based on this observation, Retrotope is creating a new category of drugs composed of
proprietary, compounds that treat degenerative diseases and improve life as we age.
Its first drug, now in clinical evaluation, treats a rare neurodegenerative disease, Friederich’s ataxia, as a rapid proof of human concept, and preclinical data support use of the drug category in other indications.